Globerson Levin Anat, (PI, TASMC) learned her MSc (2006) in Cell Biology, at Tel Aviv University and PhD (2011) at the Weizmann Institute, where she studied under Prof. Zelig Eshhar supervision. Dr. Globerson Levin research has been focused on developing immunotherapy treatment using the chimeric antigen receptor (CAR) concept. Her effort today is overcoming the immunosuppressive environment, overcoming toxicity related to the treatment and developing new methods to redirect CAR T toward the tumor site. She developed a dual CAR T cell treatment towards multiple myeloma, which is now moving ahead to a clinical trial. She was involved in the establishment of the immunotherapy center at TASMC (I-ACT), which will be treating patients using cell therapy. Dr. Globerson received several grants including CRBC, ISF, Kamin, and Persol foundation grants. She also possess several patents related to CAR T inventions.